Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Hyundai ADM Bio lnc. Korean CRO offering end-to-end clinical trial services for pharma & bio ventures.	South Korea	187660
HYUNDAI BIOSCIENCE CO., LTD. Clinical-stage biotech developing safer antiviral & anticancer drugs via advanced drug delivery systems.	South Korea	048410
iBio, Inc. AI-powered biotech developing antibody therapeutics for cardiometabolic diseases and obesity.	United States of America	IBIO
Ibotta, Inc. A performance marketing platform offering cash-back rewards to consumers from CPG brands.	United States of America	IBTA
ICON PLC Global CRO providing outsourced development & commercialization for pharma, biotech & device firms.	United States of America	ICLR
IDEAYA Biosciences, Inc. Clinical-stage firm developing precision cancer therapies via synthetic lethality.	United States of America	IDYA
IMGT Corporation Limited Develops a drug delivery platform using ultrasound and nanotech for oncology.	South Korea	456570
IMMERSION CORP Licenses patented haptic feedback technology for mobile, gaming, and automotive interfaces.	United States of America	IMMR
IMMUNIC, INC. Developing oral small molecule therapies for chronic inflammatory and autoimmune diseases.	United States of America	IMUX
IMMUTEP Ltd Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.	United States of America	IMMP